{"organizations": [], "uuid": "ce33284217e6c38afeb55dfdbff293f71953433a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-endo-expects-2018-us-generic-pharm/brief-endo-expects-2018-u-s-generic-pharmaceuticals-revenue-to-decline-in-the-mid-to-high-30-pct-range-versus-prior-year-idUSFWN1QH0VA", "country": "US", "domain_rank": 408, "title": "BRIEF-Endo Expects 2018 U.S. Generic Pharmaceuticals Revenue To Decline In The Mid-To High 30 Pct Range Versus Prior Year", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T16:58:00.000+02:00", "replies_count": 0, "uuid": "ce33284217e6c38afeb55dfdbff293f71953433a"}, "author": "", "url": "https://www.reuters.com/article/brief-endo-expects-2018-us-generic-pharm/brief-endo-expects-2018-u-s-generic-pharmaceuticals-revenue-to-decline-in-the-mid-to-high-30-pct-range-versus-prior-year-idUSFWN1QH0VA", "ord_in_thread": 0, "title": "BRIEF-Endo Expects 2018 U.S. Generic Pharmaceuticals Revenue To Decline In The Mid-To High 30 Pct Range Versus Prior Year", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s. generi", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters) - endo international plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News February 27, 2018 / 2:59 PM / Updated 16 minutes ago BRIEF-Endo Expects 2018 U.S. Generic Pharmaceuticals Revenue To Decline In The Mid-To High 30 Pct Range Versus Prior Year Reuters Staff 1 Min Read Feb 27 (Reuters) - Endo International Plc: * ENDO CFO SAYS ,“WE EXPECT 2018 U.S. GENERIC PHARMACEUTICALS REVENUE TO DECLINE IN THE MID- TO HIGH 30% RANGE VERSUS PRIOR YEAR” - CONF CALL * ENDO CFO SAYS ,“U.S. BRANDED SPECIALTY AND ESTABLISHED PHARMACEUTICALS REVENUE IS EXPECTED TO DECLINE IN THE LOW TEENS VERSUS PRIOR YEAR” - CONF CALL * ENDO CFO SAYS U.S. BRANDED STERILE INJECTABLES REVENUE IS EXPECTED TO GROW IN THE LOW DOUBLE-DIGIT PERCENTAGE RANGE VERSUS PRIOR YEAR - CONF CALL * ENDO CFO SAYS INTERNATIONAL SEGMENT REVENUE IS EXPECTED TO DECLINE IN THE HIGH 40S PERCENTAGE RANGE - CONF CALL Further company coverage:", "external_links": [], "published": "2018-02-27T16:58:00.000+02:00", "crawled": "2018-02-27T17:26:24.000+02:00", "highlightTitle": ""}